190 results on '"Horning, SJ"'
Search Results
152. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
- Author
-
Kwak LW, Wilson M, Weiss LM, Doggett R, Dorfman RF, Warnke RA, and Horning SJ
- Subjects
- Actuarial Analysis, Adult, Aged, Bleomycin administration & dosage, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Female, Humans, Immunophenotyping, Lymphoma, B-Cell immunology, Lymphoma, B-Cell mortality, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse mortality, Lymphoma, T-Cell immunology, Lymphoma, T-Cell mortality, Male, Methotrexate administration & dosage, Middle Aged, Prednisolone administration & dosage, Prednisone administration & dosage, Prognosis, Retrospective Studies, Survival Rate, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, B-Cell drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, T-Cell drug therapy
- Abstract
Although previous studies have suggested a relatively poor prognosis for some patients with peripheral T-cell lymphoma, the clinical significance of immunologic phenotype in diffuse large-cell lymphoma (DLCL) remains controversial. One hundred one patients with a uniform morphologic diagnosis of DLCL treated at Stanford between 1975 and 1986 with cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), vincristine, and prednisone (CHOP), methotrexate, bleomycin, Adriamycin, cyclophosphamide, vincristine, and dexamethasone ([M]BACOD), or methotrexate, Adriamycin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) chemotherapy were studied with regard to immunologic phenotype. Immunologic analysis, performed on frozen or paraffin-embedded tissue, identified 77 cases of B-cell origin, 21 cases of T-cell origin, and three cases that lacked B-cell or T-cell markers. Analysis of complete remission (CR) rates (84% v 95%), 5-year actuarial freedom from disease progression (38% v 53%), and 5-year actuarial overall survival (52% v 79%) showed no statistically significant differences in prognosis between B- and T-cell patients, respectively. The 5-year actuarial survival of patients with stage IV T-cell DLCL (56%) also did not differ in a statistically significant way from stage IV B-cell patients (36%). We conclude that treatment selection for DLCL should not be based on immunologic phenotype alone.
- Published
- 1991
- Full Text
- View/download PDF
153. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients.
- Author
-
Chao NJ, Duncan SR, Long GD, Horning SJ, and Blume KG
- Subjects
- Adult, Drug Administration Schedule, Hemorrhage etiology, Humans, Lung Diseases etiology, Methylprednisolone administration & dosage, Middle Aged, Prednisone administration & dosage, Pulmonary Alveoli, Transplantation, Autologous, Bone Marrow Transplantation adverse effects, Hemorrhage drug therapy, Lung Diseases drug therapy, Methylprednisolone therapeutic use, Prednisone therapeutic use
- Published
- 1991
- Full Text
- View/download PDF
154. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
- Author
-
Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, and Blume KG
- Subjects
- Carmustine administration & dosage, Combined Modality Therapy, Cyclophosphamide administration & dosage, Drug Evaluation, Etoposide administration & dosage, Follow-Up Studies, Hodgkin Disease drug therapy, Hodgkin Disease surgery, Humans, Lymphoma, Non-Hodgkin drug therapy, Lymphoma, Non-Hodgkin surgery, Prospective Studies, Transplantation, Autologous, Whole-Body Irradiation, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation, Hodgkin Disease therapy, Lymphoma, Non-Hodgkin therapy
- Abstract
Seventy-seven Hodgkin's disease and non-Hodgkin's lymphoma (NHL) patients received high-dose etoposide in combination with cyclophosphamide and either fractionated total body irradiation (TBI) (n = 28) or carmustine (n = 49) prior to autologous bone marrow transplantation. Marrow from NHL patients was purged in vitro with a panel of monoclonal B- and T-cell antibodies and complement. Six toxic deaths (8%) occurred, all in patients who received carmustine. With a median follow-up of 1 year, 57 patients are alive and free from progressive disease. The 1-year actuarial survival and freedom from progression are 85 and 73% in fractionated TBI/etoposide/cyclophosphamide-treated patients and 79 and 72% in carmustine/etoposide/cyclophosphamide-treated patients. Forty-five of these patients participated in prospective trials for which eligibility criteria were (1) less than 25% curability with conventional therapy; (2) achievement of minimal disease state with conventional therapy; and (3) transplantation early in the course of disease. One-year actuarial survival for 18 patients with relapsed Hodgkin's disease is 80% and for 21 relapsed intermediate and high-grade NHL patients, 70%. One NHL Burkitt's patient was transplanted on a protocol for high-risk intermediate and high-grade NHL in first remission. Five patients with follicular mixed or small cleaved NHL were also transplanted in first remission.
- Published
- 1991
- Full Text
- View/download PDF
155. The Stanford Hodgkin's disease (HD) studies--an update.
- Author
-
Horning SJ
- Subjects
- Adult, Bone Marrow Transplantation, California, Hodgkin Disease surgery, Humans, Pilot Projects, Prospective Studies, Hodgkin Disease therapy
- Abstract
Successive, prospective clinical trials for adults with HD have been conducted from 1962-1991. With approximately 75% of patients in continuous remission as a result of current therapy, attention may be focused on reducing treatment complications for the majority of patients and improving efficacy in selected, high risk populations. This overview will describe recently completed and ongoing clinical trials at Stanford University which address these therapeutic objectives.
- Published
- 1991
156. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
- Author
-
Kwak LW, Halpern J, Olshen RA, and Horning SJ
- Subjects
- Aged, Analysis of Variance, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Administration Schedule, Female, Humans, Lymphoma, Non-Hodgkin drug therapy, Male, Middle Aged, Multivariate Analysis, Prognosis, Proportional Hazards Models, Regression Analysis, Lymphoma, Non-Hodgkin mortality
- Abstract
While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed even with intensive combination chemotherapy regimens. In order to study the prognostic significance of actual dose intensity of chemotherapy in DLCL, we retrospectively analyzed 115 previously untreated patients treated as Stanford between 1975 and 1986 with cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), vincristine, and prednisone (CHOP), methotrexate, bleomycin, Adriamycin, cyclophosphamide, vincristine, and dexamethasone ([M]BACOD), or methotrexate, Adriamycin, cyclosphosphamide, vincristine, prednisone, and bleomycin (MACOP-B). The actual relative dose intensity (RDI), the amount of drug actually administered to each patient during the first 12 weeks of therapy, was calculated as standardized to CHOP and analyzed in addition to clinical factors prognostic for survival by univariate analysis. Multivariate recursive partitioning (tree-structured) survival analysis identified the actual RDI of Adriamycin greater than 75% as the single most important predictor of survival. A model incorporating the actual RDI of Adriamycin and performance status, in combination with serum lactate dehydrogenase (LDH) and extranodal disease, defined three overall prognostic groups of patients with respective 3-year survival rates of 89%, 63%, and 18%. The three prognostic groups remained distinct, even when restricted to complete responders. This model was also predictive of survival when dose intensity was analyzed relative to the optimum dose defined for each of the three regimens and when applied to a subgroup of patients aged 50 years or younger. We conclude that actual RDI is an important prognostic factor for survival in DLCL and that analysis of RDI early in the course of treatment may allow modification of the treatment plan.
- Published
- 1990
- Full Text
- View/download PDF
157. Bone marrow transplantation for hematologic malignancies: the Stanford experience.
- Author
-
Chao NJ, Amylon MD, Long GD, Negrin RS, Hoppe RT, Horning SJ, and Blume KG
- Subjects
- Adult, Anemia, Aplastic surgery, California, Child, Female, Humans, Immunosuppression Therapy methods, Male, Retrospective Studies, Thalassemia surgery, Transplantation, Autologous, Transplantation, Homologous, Bone Marrow Transplantation immunology, Leukemia surgery, Lymphoma, Non-Hodgkin surgery
- Abstract
Allogeneic and autologous BMTs are highly effective and successful treatment modalities for selected patients. Use of BMT earlier in the course of disease yields better results when compared to patients with more advanced disease. Recent advances such as use of cloned growth factors, cytokines, etc..., will continue to contribute to lessen morbidity and mortality. Finally, as investigators understand, prevent, and treat expected side effects from BMTs, the patients' burden in terms of physical, psychological, and financial costs should lessen substantially.
- Published
- 1990
158. Sequential equilibrium gated radionuclide angiocardiography for the detection of doxorubicin cardiotoxicity.
- Author
-
Pauwels EK, Horning SJ, and Goris ML
- Subjects
- Adolescent, Adult, Aged, Female, Heart drug effects, Humans, Male, Methods, Middle Aged, Radionuclide Imaging, Sodium Pertechnetate Tc 99m, Stroke Volume drug effects, Doxorubicin toxicity, Heart diagnostic imaging
- Abstract
Right and left ventricular ejection fractions (RVEF and LVEF) were studied at rest, during exercise, and in the immediate post-exercise period (recovery) in 23 patients treated with doxorubicin. Ejection fractions were determined using equilibrium gated radionuclide angiography and non-interactive computer processing. Two effects of doxorubicin emerged: (1) The LVEF at rest and the maximal LVEF reached during the stress test decreased as a function of the cumulative dose expressed in mg/m2. (2) When two measurements were performed before and after an interval dose of less than 100 mg/m2, the resting and maximal LVEF showed an increase, but at higher interval doses, those values showed a decrease. In general, the effect of an incremental dose was not a function of the cumulative dose. No significant changes were detected in RVEF, and LVEF at standardized exercise levels did not correlate with cumulative doses or change as a function of interval dosage.
- Published
- 1983
- Full Text
- View/download PDF
159. Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications.
- Author
-
Tseng A Jr, Horning SJ, Freiha FS, Resser KJ, Hannigan JF Jr, and Torti FM
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Castration, Chorionic Gonadotropin blood, Dysgerminoma pathology, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Physical Examination, Prognosis, Teratoma pathology, Testicular Neoplasms blood, Testicular Neoplasms drug therapy, Time Factors, Breast pathology, Gynecomastia pathology, Testicular Neoplasms pathology
- Abstract
Eighty-one patients with advanced testicular cancer were evaluated for gynecomastia or severe breast tenderness at diagnosis and after platinum-based chemotherapy. The prognostic significance of gynecomastia in these two settings was explored. At presentation, 10% (8 patients) had gynecomastia or breast tenderness and elevated HCG levels. The likelihood of gynecomastia was greater with increasing HCG level (P = 0.002). However, gynecomastia at presentation was a more powerful independent discriminant of poor survival than the initial HCG level by multivariate analysis (P = 0.004). Fifteen percent (12 patients) developed transient gynecomastia after chemotherapy not attributable to other known causes. HCG levels were normal. Endocrine evaluation typically revealed elevated FSH, LH, and estradiol/testosterone ratios. This may have reflected damage to testicular germinal epithelium. All 12 patients are alive without disease in contrast to the 8 patients who had gynecomastia at diagnosis. Therapy decisions should therefore be based on the time of onset of gynecomastia and in the context of appropriate clinical markers and evaluation.
- Published
- 1985
- Full Text
- View/download PDF
160. Phase I study of human leukocyte interferon in patients with advanced cancer.
- Author
-
Horning SJ, Levine JF, Meyer M, Merigan TC, and Rosenberg SA
- Subjects
- Adult, Aged, Drug Evaluation, Female, Humans, Interferon Type I administration & dosage, Interferon Type I adverse effects, Interferons blood, Kinetics, Male, Middle Aged, Time Factors, Interferon Type I therapeutic use, Neoplasms therapy
- Abstract
Seventeen patients with disseminated cancer were treated with a human leukocyte interferon preparation in doses ranging from 3 X 10(6) to 50 X 10(6) IU daily for 30 days. Doses above 18 X 10(6) IU were considered intolerable in this schedule of administration due to severe fatigue and weight loss. Serum concentrations of interferon were lower than those achieved with either partially pure native or recombinant leukocyte interferon. Three of 17 patients in this study showed minimal evidence of tumor regression. Two patients treated at doses of 18 X 10(6), 36 X 10(6), and 50 X 10(6) IU also received a 5 X 10(6)-IU dose of a second human leukocyte interferon preparation. The latter resulted in less toxicity but similar serum levels. These results suggest that human leukocyte interferons prepared in the same manner may differ significantly in their in vivo biologic properties.
- Published
- 1983
161. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.
- Author
-
Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, and Dziewanowski Z
- Subjects
- Adult, Biological Availability, DNA, Recombinant, Drug Evaluation, Female, Humans, Interferons adverse effects, Interferons metabolism, Kinetics, Male, Middle Aged, Interferons therapeutic use, Neoplasms drug therapy
- Abstract
Sixteen patients with advanced cancer were treated with recombinant-DNA-produced pure leukocyte A interferon (IFLrA) intramuscularly in doses ranging from 3 to 198 X 10(6) units. with interval periods of 72 to 96 hours between doses. At the two lowest doses of 3 and 9 million units, there was a cross-over evaluation between IFLrA and partially pure leukocyte interferon (IFN-C) produced from human cells. THe maximum observed serum concentration of IFLrA measured by enzyme immunoassay and bioassay increased with increasing doses. The mean serum concentrations of IFLrA and IFN-C were similar. Clinical effects produced by IFLrA and IFN-C were similar, including fever, chills, myalgias, headache fatigue, and reversible leukopenia and granulocytopenia. Eight patients had transient and mild numbness of the hands or feet, or both. Three patients developed low titers of antibody to IFLrA, Seven of 16 patients showed objective evidence of tumor regression during the study.
- Published
- 1982
- Full Text
- View/download PDF
162. Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma.
- Author
-
Weiss LM, Strickler JG, Dorfman RF, Horning SJ, Warnke RA, and Sklar J
- Subjects
- Aged, Biopsy, Clone Cells, Female, Genes, MHC Class II, Genetic Techniques, Humans, Immunoblastic Lymphadenopathy genetics, Immunoenzyme Techniques, Lymph Nodes pathology, Lymphoma genetics, Male, Middle Aged, Receptors, Antigen, T-Cell genetics, Spleen pathology, Immunoblastic Lymphadenopathy pathology, Lymphoma pathology, T-Lymphocytes pathology
- Abstract
Ten cases of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) and AILD-like lymphoma were studied by immunophenotypic and immunogenotypic analysis. All specimens were found to have a predominance of T cells by immunophenotypic analysis. DNA hybridization analyses showed three of five specimens of AILD and five of six specimens of AILD-like lymphoma to contain clonal rearrangements of the beta T-cell receptor gene. No rearrangements of the heavy or light chain immunoglobulin genes were seen in any case. A single case showed a progression of AILD with a germ-line pattern of beta T-cell receptor DNA to AILD-like lymphoma with detectable clonal rearrangements for beta T-cell receptor DNA. These results suggest that many, but not all, cases diagnosed histologically as AILD or AILD-like lymphoma contain a clonal proliferation of T-lymphocytes.
- Published
- 1986
163. Transferrin receptor expression by non-Hodgkin's lymphomas. Correlation with morphologic grade and survival.
- Author
-
Medeiros LJ, Picker LJ, Horning SJ, and Warnke RA
- Subjects
- Antibodies, Monoclonal, California, Humans, Leukemia, Lymphoid metabolism, Lymphoma, Non-Hodgkin classification, Lymphoma, Non-Hodgkin mortality, Lymphoma, Non-Hodgkin pathology, Prognosis, Receptors, Transferrin immunology, Lymphoma, Non-Hodgkin analysis, Neoplasm Proteins analysis, Receptors, Transferrin analysis
- Abstract
The monoclonal antibody OKT9 was applied to cryostat sections of 267 non-Hodgkin's lymphomas and related neoplasms. It was found that the transferrin receptor is expressed by a wide variety of B- and T-lineage non-Hodgkin's lymphomas. The OKT9 staining also was loosely correlated with the three morphologic grades of non-Hodgkin's lymphomas identified by the International Working Formulation. In general, higher grade lymphomas more often and more intensely expressed the T9 antigen. However, transferrin receptor expression by certain histologic subtypes of lymphoma did not correlate with their morphologic grade: low-grade follicular lymphomas expressed the T9 antigen more frequently than diffuse low-grade lymphomas; diffuse small cleaved cell lymphomas were stained by OKT9 less often than other histologic subtypes of intermediate-grade lymphomas; and diffuse immunoblastic lymphomas expressed transferrin receptors less often than the other high-grade histologic subtypes of non-Hodgkin's lymphoma. Intermediate lymphocytic lymphomas, not recognized in the International Working Formulation, were infrequently and weakly stained by OKT9 in a manner similar to diffuse low-grade lymphomas. We obtained clinical follow-up data on 43 individuals with chronic lymphocytic leukemia/small lymphocytic lymphoma and 64 individuals with diffuse large cell and immunoblastic lymphoma. Transferrin receptor expression in these two groups did not correlate significantly with survival.
- Published
- 1988
- Full Text
- View/download PDF
164. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.
- Author
-
Tseng A Jr, Jacobs C, Coleman CN, Horning SJ, Lewis BJ, and Rosenberg SA
- Subjects
- Administration, Oral, Adolescent, Adult, Aged, Anemia chemically induced, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Etoposide administration & dosage, Female, Humans, Leukopenia chemically induced, Lomustine administration & dosage, Male, Methotrexate administration & dosage, Middle Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease drug therapy
- Abstract
Thirty-two patients with recurrent Hodgkin's disease have been treated with an oral regimen employing lomustine (CCNU, 100 mg/m2 orally on Day 1); etoposide (VP-16, 100 mg/m2 orally on Days 1-3 and 21-23); and methotrexate (30 mg/m2 orally on Days 1, 8, 21, and 28). The regimen was repeated every 6 weeks. Most patients had been treated with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine); 20 had had prior irradiation. Lymph node was the predominant site of disease and the majority of patients had B symptoms. Four patients achieved complete response (13%), with a median duration of 33+ months, and 11 achieved partial response (34%), with a median duration of 5 months, for an overall response rate of 47%. The major toxic effect was severe myelosuppression, which occurred in six patients; there were no treatment-related deaths. This oral regimen was easy to administer in heavily pretreated patients with poor venous access and had minimal toxicity.
- Published
- 1987
165. Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial.
- Author
-
Horning SJ, Merigan TC, Krown SE, Gutterman JU, Louie A, Gallagher J, McCravey J, Abramson J, Cabanillas F, and Oettgen H
- Subjects
- Adolescent, Adult, Aged, Evaluation Studies as Topic, Fatigue etiology, Female, Fever etiology, Humans, Interferon Type I adverse effects, Interferon Type I blood, Male, Middle Aged, Hodgkin Disease therapy, Interferon Type I therapeutic use, Lymphoma therapy
- Abstract
Forty-nine patients with non-Hodgkin's lymphoma or Hodgkin's disease were entered into a multi-institutional phase II trial to evaluate the antitumor activity of human interferon alpha, prepared from buffy coats. Interferon alpha was administered intramuscularly in doses of 1 X 10(6) u, 3 X 10(6) u or 9 X 10(6) u daily for 30 days. Objective partial responses were seen in 3 of 18 patients with nodular lymphoma, all at the 9 X 10(6) u dose. Interferon alpha was not observed to be of therapeutic benefit in the other subtypes of non-Hodgkin's lymphoma or Hodgkin's disease. The major toxicities consisted of fatigue, fever, myalgias and weight loss. Serum interferon levels obtained 3 to 4 hours after injection varied widely, even among patients treated at the same dose level. Despite the relatively low doses of interferon used and the brief period of administration, this study extends the earlier observations of the antitumor effect of interferon in nodular lymphoma. These results are discussed in relation to the cumulative experience in human lymphoma using alpha interferons induced in human leukocytes and those produced in bacteria by recombinant DNA techniques.
- Published
- 1985
- Full Text
- View/download PDF
166. Clinical and pathologic features of follicular large cell (nodular histiocytic) lymphoma.
- Author
-
Horning SJ, Weiss LM, Nevitt JB, and Warnke RA
- Subjects
- Actuarial Analysis, Female, Follow-Up Studies, Humans, Lymphoma, Follicular therapy, Lymphoma, Large B-Cell, Diffuse therapy, Male, Neoplasm Staging, Lymphoma, Follicular pathology, Lymphoma, Large B-Cell, Diffuse pathology
- Abstract
Clinicopathologic correlations were made in 50 patients with follicular large cell (FLC) lymphoma to better define the influence of a variety of clinical and pathologic features on survival and the potential for continuous freedom from disease. The 5- and 10-year actuarial survivals for the entire group of patients are 77% and 63%, respectively, but disease-free survival is only 46% at 5 years and 22% at 10 years. No significant survival differences were found with various treatment approaches, although a single relapse occurred after 3 years among patients treated with modern combination chemotherapy containing doxorubicin. Median survivals of approximately 10 years despite recurrent disease are characteristic of the majority of follicular lymphomas. Furthermore, the reproducibility of cytologic diagnosis among follicular lymphomas is known to be variable. At this time, it is unclear whether intensive chemotherapy will cure a significant number of FLC patients or novel approaches are necessary as for the other follicular lymphomas.
- Published
- 1987
- Full Text
- View/download PDF
167. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer.
- Author
-
Horning SJ, Levine JF, Miller RA, Rosenberg SA, and Merigan TC
- Subjects
- Cytotoxicity, Immunologic, Fatigue etiology, Female, Fever etiology, Headache etiology, Humans, Interferons adverse effects, Interferons immunology, Lymphocytes immunology, Male, beta 2-Microglobulin analysis, DNA, Recombinant, Interferons therapeutic use, Leukocytes metabolism, Neoplasms therapy
- Abstract
The clinical and immunologic effects of a biosynthetic human leukocyte interferon, recombinant leukocyte A interferon (IFL-rA), are reported in eight patients with advanced cancer. Single escalating doses from 3 X 10(6) units to 198 X 10(6) units were given by intramuscular injection in a phase I study. Major toxic effects included pyrexia, fatigue, myalgia, and headache. Data on the effects of IFL-rA on lymphocyte subpopulations and peripheral blood mononuclear-cell surface beta 2-microglobulin are presented. Four of eight patients had objective tumor regression, indicating that further investigation of this biologically active material is warranted.
- Published
- 1982
168. Small lymphocytic lymphoma.
- Author
-
Morrison WH, Hoppe RT, Weiss LM, Picozzi VJ Jr, and Horning SJ
- Subjects
- Actuarial Analysis, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Lymph Nodes pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell pathology
- Abstract
The clinical course of 54 patients with small lymphocytic lymphoma (SL) was reviewed. The majority of patients had disseminated lymphoma at the time of diagnosis; 14 patients (26%) presented with Ann Arbor stage I and II disease. Five- and 10-year survival for all patients was 76% and 49%. The only clinicopathologic features identified that predicted a shortened survival were the presence or absence of systemic (B) symptoms (15% v 63% at 10 years, P = .01) and a diffuse rather than pseudofollicular nodal architecture (47% v 87% at 10 years, P = .04). Initial bone marrow involvement was not an adverse prognostic factor for patients who presented with stage III and IV disease. Ten patients developed a marked lymphocytosis consistent with progression to a leukemic phase (chronic lymphocytic leukemia [CLL]). These ten patients had a median initial lymphocyte count of 2,790, compared with 1,580 for those patients who did not progress to CLL (P = .0001). Developing CLL did not adversely affect survival (P = .48). Thirty-seven patients were treated with various combinations of radiation and chemotherapy; 17 patients received no initial therapy. Ten-year freedom from relapse (FFR) for stage I and II patients treated with irradiation was 80% and 62%; FFR for stage III and IV treated patients was 11%. Despite the marked differences in FFR, no statistically significant difference in survival could be demonstrated between the various stages. Selected patients with advanced SL received no initial therapy; these patients had a 10-year survival that was not statistically different from the immediately treated stage III and IV patients. Patients with stage I and II SL should be treated with irradiation; prolonged FFR and possibly cure of the disease can be achieved in these patients.
- Published
- 1989
- Full Text
- View/download PDF
169. Histiocytic malignancies. Morphologic, immunologic, and enzymatic heterogeneity.
- Author
-
Turner RR, Wood GS, Beckstead JH, Colby TV, Horning SJ, and Warnke RA
- Subjects
- Adolescent, Adult, Aged, Child, Female, Frozen Sections, Humans, Liver Neoplasms enzymology, Liver Neoplasms immunology, Liver Neoplasms pathology, Lymphatic Diseases enzymology, Lymphatic Diseases immunology, Lymphoma enzymology, Lymphoma immunology, Male, Middle Aged, Skin Neoplasms enzymology, Skin Neoplasms immunology, Skin Neoplasms pathology, Splenic Neoplasms enzymology, Splenic Neoplasms immunology, Splenic Neoplasms pathology, Staining and Labeling, T-Lymphocytes, Lymphatic Diseases pathology, Lymphoma pathology
- Abstract
We have studied 14 hematopoietic malignancies with histologic features of histiocytic differentiation, using frozen section immunologic stains, plastic section enzyme histochemistry, and paraffin section immunocytochemistry. There was morphologic, immunologic, and enzymatic heterogeneity, including findings in seven cases that suggested differentiation toward specialized subsets of histiocytes. Four cases expressed a mature monocyte/macrophage phenotype by frozen section monoclonal antibody staining and three of these had histologic patterns diagnostic of malignant histiocytosis; two other cases had ATPase and S100 protein reactivity and morphologic features consistent with interdigitating (reticulum) cell proliferations; and one case was alkaline phosphatase positive, suggestive of differentiation toward fibroblastic reticulum cells. Four cases had histologic findings consistent with malignant histiocytosis, but weak or unreactive staining patterns and were considered poorly differentiated histiocytic or primitive hematopoietic malignancies. Three other cases, also morphologically consistent with malignant histiocytosis, were identified as probably T-cell lymphomas. The morphologic and phenotypic characteristics of non-neoplastic histiocytes and dendritic cell types and their related neoplasms are discussed. Histiocytic malignancies comprise a diverse group that can be identified and subclassified by immunologic and enzymatic techniques.
- Published
- 1984
170. Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment.
- Author
-
Horning SJ, Carrier EK, Rouse RV, Warnke RA, and Michie SA
- Subjects
- Actuarial Analysis, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma mortality, Carcinoma ultrastructure, Diagnosis, Differential, Female, Humans, Immunoenzyme Techniques, Lymphoma mortality, Lymphoma ultrastructure, Male, Middle Aged, Phenotype, Carcinoma pathology, Lymphoma pathology
- Abstract
Malignant lymphoma is frequently diagnosed when immunohistochemical techniques are applied to otherwise unclassified neoplasms. In this analysis of 35 patients with a histologically unclassified neoplasm that expressed leukocyte-common antigen(s) (LCA), actuarial survival was 63%, and 45% of patients were free from disease progression at 30 months following treatment as for lymphoma. The clinical features at diagnosis and the results of combination chemotherapy were found to be similar to a group of patients with a diagnosis of diffuse large-cell lymphoma (DLCL) concurrently treated at this institution. This study further emphasizes the importance of improved diagnostic techniques in the management of histologically unclassified tumors.
- Published
- 1989
- Full Text
- View/download PDF
171. Current Stanford clinical trials for Hodgkin's disease.
- Author
-
Hoppe RT, Horning SJ, Hancock SL, and Rosenberg SA
- Subjects
- Humans, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Hodgkin Disease therapy
- Published
- 1989
- Full Text
- View/download PDF
172. Numbers of host "helper" T cells and proliferating cells predict survival in diffuse small-cell lymphomas.
- Author
-
Medeiros LJ, Picker LJ, Gelb AB, Strickler JG, Brain SW, Weiss LM, Horning SJ, and Warnke RA
- Subjects
- Adult, Aged, Aged, 80 and over, B-Lymphocytes classification, B-Lymphocytes pathology, Female, Humans, Leukocyte Count, Lymphocyte Activation, Male, Middle Aged, Prognosis, T-Lymphocytes classification, Lymphoma, Non-Hodgkin pathology, T-Lymphocytes pathology, T-Lymphocytes, Helper-Inducer pathology
- Abstract
Diffuse small-cell lymphomas of B-lineage comprise a group of immunophenotypically related lymphoid malignancies that display variable clinical aggressiveness. We compared a variety of clinical, pathologic, and immunologic characteristics of 64 B-lineage diffuse small-cell lymphomas to patient survival in an effort to define prognostically relevant subtypes of these neoplasms. Neither clinical parameters nor histological subclassification correlated with patient outcome. In contrast, three immunologic features of these lymphomas showed a statistically significant relationship with actuarial survival. Neoplasms that manifested greater than or equal to 25% Ki-67+ cells (proliferation-associated antigen), less than 25% Leu 4+ cells (pan-T antigen), or less than 15% Leu 3+ cells (helper/inducer T-subset antigen) were associated with significantly decreased patient survival as compared to neoplasms with the reverse phenotype (P = .02, P = .003, P = .0005, respectively). Leu 3 findings were of particular importance in initial biopsies (P = .0007), while the Ki-67 findings were significant regardless of time of biopsy (P = .01 for biopsies at diagnosis and P = .004 for other biopsies). These data indicate that immunologic analysis can demonstrate subsets of diffuse small-cell lymphoma with different biologic potential, and suggest that such analysis be included in the routine work-up of patients with this type of neoplasm.
- Published
- 1989
- Full Text
- View/download PDF
173. Expression of LFA-1 in non-Hodgkin's lymphoma.
- Author
-
Medeiros LJ, Weiss LM, Picker LJ, Clayberger C, Horning SJ, Krensky AM, and Warnke RA
- Subjects
- Humans, Immunoenzyme Techniques, In Vitro Techniques, Lymphocyte Function-Associated Antigen-1, Antigens, Differentiation immunology, Lymphoma, Non-Hodgkin immunology, Membrane Glycoproteins immunology
- Abstract
Lymphocyte function-associated antigen 1 (LFA-1) is a glycoprotein involved in virtually all aspects of the immune response requiring direct cell to cell contact. It has been suggested that lack of LFA-1 expression in lymphomas may represent a mechanism of escape from immunologic surveillance. We investigated the expression of LFA-1 in a series of more than 250 lymphoid neoplasms and reactive lymphoid proliferations using a frozen section immunoperoxidase technique. LFA-1 was expressed by all lymphoid populations in the reactive cases. In contrast, absence of LFA-1 alpha or beta chains was found in 44% of non-Hodgkin's lymphomas, including 50% of B-cell lymphomas. These findings suggest that loss of LFA-1 expression may be of great use in the differential diagnosis of benign versus malignant lymphoproliferations. Eighty percent of initial biopsy specimens of low-grade lymphoma exhibited LFA-1 expression, whereas only 8% of recurrent specimens retained expression of both LFA-1 subunits. However, we found no correlation between LFA-1 expression and clinical course in a series of 64 patients with diffuse large cell lymphomas.
- Published
- 1989
- Full Text
- View/download PDF
174. Durable remissions in stage III follicular lymphoma: interpret with caution.
- Author
-
Horning SJ
- Subjects
- Combined Modality Therapy, Humans, Remission Induction, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Follicular drug therapy
- Published
- 1987
- Full Text
- View/download PDF
175. AIDS and Hodgkin's disease.
- Author
-
Schoeppel SL, Hoppe RT, Dorfman RF, Horning SJ, Chew TG, Weiss LM, and Collier AC
- Subjects
- Homosexuality, Humans, Lymphatic Diseases complications, Male, Risk, Syndrome, Acquired Immunodeficiency Syndrome etiology, Hodgkin Disease complications
- Published
- 1985
176. Female reproductive potential after treatment for Hodgkin's disease.
- Author
-
Horning SJ, Hoppe RT, Kaplan HS, and Rosenberg SA
- Subjects
- Adolescent, Adult, Antineoplastic Agents administration & dosage, Drug Therapy, Combination, Female, Hodgkin Disease drug therapy, Hodgkin Disease radiotherapy, Humans, Lymphatic System radiation effects, Menopause, Menstruation, Ovary radiation effects, Pregnancy, Retrospective Studies, Hodgkin Disease therapy, Reproduction radiation effects
- Abstract
The probability of maintaining ovarian function, becoming pregnant, and delivering a normal child is important to young women anticipating successful therapy for Hodgkin's disease. In this study, reproductive function was retrospectively examined in 103 women 40 years old or younger who had undergone treatment for Hodgkin's disease with total-lymphoid irradiation (TLI) alone, combination chemotherapy, or combined TLI and chemotherapy. Infertility was directly related to gonadal exposure to therapy and to age at treatment. Twenty women became pregnant after receiving total-nodal irradiation or combination chemotherapy or both. No fetal wastage occurred, and no birth defects were seen in the 24 infants born to these women. Even after intensive treatment programs, women successfully treated for Hodgkin's disease have become pregnant and delivered phenotypically normal children.
- Published
- 1981
- Full Text
- View/download PDF
177. Combined modality therapy for stage I-II large cell lymphoma.
- Author
-
Prestidge BR, Horning SJ, and Hoppe RT
- Subjects
- Actuarial Analysis, Adult, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Lymphoma mortality, Male, Radiotherapy Dosage, Statistics as Topic, Time Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma therapy, Radiotherapy, High-Energy
- Abstract
Between January 1978 and December 1986, 94 patients with Stage I-II large cell lymphoma were evaluated at Stanford University Medical Center and treated with a combination of chemotherapy (CTX) and irradiation (XRT). The predominant histology was diffuse large cell (78), followed by immunoblastic (7), follicular large cell (6), and diffuse mixed small and large cell lymphoma (3). Twenty-three patients had Stage I and 71 had Stage II disease. Fifty-one had extranodal involvement (13 IE, 38 IIE), and 11 had B symptoms (2 IB, 9 IIB). Lymphoma was supradiaphragmatic in 58 patients, infradiaphragmatic in 21, and only in extranodal sites in 15. Patients received either involved (81) or extended (13) field XRT with a median dose of 40 Gy and combination CTX with 2 to 9 cycles (median 6) of either CHOP (68), M-BACOD (8), C-MOPP (8), MACOP-B (4), or other (6). Seventy-two patients remain with no evidence of disease, 21 are dead with disease, and one suffered an intercurrent death. Among the 19 patients who relapsed, there were six failures within the XRT field only, two within and outside the XRT field, and 11 outside of the XRT fields only. Actuarial survival and freedom from relapse (FFR) for the entire population were 74% and 72% at 5-years, respectively (33 month median follow-up). Stage I patients achieved 81% survival and 78% FFR, and Stage II patients had 72% survival and 70% FFR. In univariate and multivariate analyses, a favorable outcome was associated with the CTX-XRT-CTX sequence of therapy (p = 0.001), low LDH (p = 0.01), and small tumor bulk (p = 0.04). There were no relapses or deaths among the 21 patients receiving the "sandwich" sequence (CTX-XRT-CTX) of therapy. This series may serve as a comparison with single modality treatment programs for localized large cell lymphoma using either XRT or CTX alone.
- Published
- 1988
- Full Text
- View/download PDF
178. The natural history of initially untreated low-grade non-Hodgkin's lymphomas.
- Author
-
Horning SJ and Rosenberg SA
- Subjects
- Adult, Aged, Female, Follow-Up Studies, Humans, Lymph Nodes pathology, Lymphoma, Non-Hodgkin mortality, Lymphoma, Non-Hodgkin pathology, Male, Middle Aged, Neoplasm Regression, Spontaneous, Lymphoma mortality, Lymphoma pathology
- Abstract
To learn more about the natural history of low-grade non-Hodgkin's lymphoma, we have studied 83 patients in whom the advanced disease was initially managed without therapy. Actuarial survival was 82 per cent at 5 years and 73 per cent at 10 years. The median time until therapy was required was three years. Spontaneous regressions occurred in 19 untreated patients (23 per cent), including 30 per cent of patients with nodular, poorly differentiated lymphocytic lymphoma. Histologic transformation to an intermediate-grade or high-grade lymphoma occurred both before and after primary therapy. The actuarial risk of transformation among the initially untreated patients was similar to that in a group of patients treated at this institution immediately after diagnosis. Neither the time to histologic transformation nor the incidence of transformation was influenced by when therapy was started.
- Published
- 1984
- Full Text
- View/download PDF
179. Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin.
- Author
-
Tseng A Jr, Jacobs C, Coleman CN, Horning SJ, Lewis BJ, and Rosenberg SA
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cisplatin administration & dosage, Cytarabine administration & dosage, Drug Evaluation, Humans, Lymphoma, Non-Hodgkin pathology, Middle Aged, Teniposide administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Non-Hodgkin drug therapy
- Published
- 1987
180. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease.
- Author
-
Horning SJ, Hoppe RT, Hancock SL, and Rosenberg SA
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bleomycin administration & dosage, Bleomycin adverse effects, Combined Modality Therapy, Female, Fertility drug effects, Fertility radiation effects, Hodgkin Disease radiotherapy, Humans, Lung drug effects, Lung radiation effects, Lung Volume Measurements, Male, Methotrexate administration & dosage, Methotrexate adverse effects, Middle Aged, Prognosis, Random Allocation, Vincristine administration & dosage, Vincristine adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease drug therapy
- Abstract
Sixty-seven patients with favorable pathologic stage (PS) I and IIA or B or IIIA Hodgkin's disease were randomized to receive subtotal or total lymphoid irradiation (STLI/TLI) alone or involved field irradiation (IF) plus six cycles of a novel adjuvant chemotherapy containing vinblastine, bleomycin, and methotrexate (VBM). With a follow-up from 6 to 72 months (median, 37 months), the actuarial freedom-from-progressive disease (FFP) at 5 years is 70% after STLI/TLI and 95% after IF plus VBM. One death has occurred in the irradiation-only treatment group. The data for IF plus VBM are significantly superior to previous actuarial results at 5 years using IF alone (FFP = 35%, P less than .00001) and compare favorably with prior results with IF plus nitrogen mustard, vincristine, procarbazine, +/- prednisone (MOP[P]) chemotherapy (FFP = 80% at 5 years, P = .10). VBM is well tolerated with greater than 90% of calculated doses delivered. As anticipated, VBM has had relatively little adverse effect on male or female fertility. Selected pulmonary functions are reduced early after IF plus VBM to a greater degree than with irradiation of the mediastinum alone, but the differences are modest. Based upon our current numbers and follow-up, we can be 90% confident that VBM as an adjuvant to irradiation in favorable Hodgkin's disease is as effective, or even superior, to MOP(P) chemotherapy. Because of its lesser toxicity, adjuvant VBM may have a broader role in the management of Hodgkin's disease.
- Published
- 1988
- Full Text
- View/download PDF
181. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials.
- Author
-
Hancock SL, Hoppe RT, Horning SJ, and Rosenberg SA
- Subjects
- Actuarial Analysis, Cardiovascular Diseases etiology, Cardiovascular Diseases mortality, Clinical Trials as Topic, Combined Modality Therapy, Hodgkin Disease complications, Hodgkin Disease drug therapy, Hodgkin Disease radiotherapy, Humans, Mechlorethamine therapeutic use, Neoplasms, Multiple Primary mortality, Opportunistic Infections mortality, Prednisone therapeutic use, Procarbazine therapeutic use, Random Allocation, Retrospective Studies, Risk, Vincristine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease mortality
- Abstract
Study Objective: To assess long-term differences in mortality associated with initial Hodgkin disease therapy., Design: Retrospective review of patients treated in prospectively randomized clinical trials., Patients: Three hundred twenty-six patients with pathologic stage I, II, or III, A or B Hodgkin disease treated between 1967 and 1980 with median follow-up exceeding 14 years., Interventions: Patients at the same stage of disease were randomized to receive radiation alone (167 patients) or radiation followed by 6 cycles of mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone (MOPP) chemotherapy (159 patients) with additional therapy for progression or recurrence., Measurements and Main Results: No significant differences between treatment regimens for actuarial survival, intercurrent disease, or Hodgkin disease mortality were seen. Thirty-three patients who received radiation alone and 30 patients who received adjuvant chemotherapy died without evident Hodgkin disease. Death was caused by second neoplasms in 28 patients (relative risk, 2.35; 95% CI, 1.46 to 3.24). Six patients developed acute myelogenous leukemia or a myeloproliferative disorder after treatment including MOPP. Chemotherapy exposure varied among the 8 patients with lung cancers, 6 with gastrointestinal and 3 with other adenocarcinomas, 3 with sarcomas, 1 with diffuse large cell lymphoma, and 1 with melanoma. Acute myocardial infarction caused 9 of 17 cardiovascular disease deaths with 5 occurring in patients between the ages of 33 and 43. Nonetheless, the risk for acute myocardial infarction was not clearly increased (relative risk, 0.86; 95% CI, 0.42 to 1.57). Fifteen patients died from infection: 5, opportunistic; 5, asplenic sepsis; and 5, other pneumonias. Two patients died in accidents, and 1 died from radiation pneumonitis., Conclusions: Adjuvant MOPP chemotherapy improved freedom from relapse without significant survival benefit or impairment. Leukemogenesis was the only lethal complication associated with MOPP. Survivors of Hodgkin disease had an increased risk for death from a second neoplasm, but no apparent increased risk for death from acute myocardial infarction.
- Published
- 1988
- Full Text
- View/download PDF
182. The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease.
- Author
-
Hoppe RT, Horning SJ, and Rosenberg SA
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Clinical Trials as Topic, Combined Modality Therapy, Hodgkin Disease drug therapy, Hodgkin Disease pathology, Humans, Neoplasm Staging, Hodgkin Disease radiotherapy
- Published
- 1985
183. Phase I study of recombinant human interferon beta in patients with advanced cancer.
- Author
-
Hu E and Horning SJ
- Subjects
- Chemical and Drug Induced Liver Injury, Dose-Response Relationship, Drug, Drug Evaluation, Hematopoiesis drug effects, Humans, Immunotherapy, Interferon Type I adverse effects, Kidney Diseases chemically induced, Recombinant Proteins therapeutic use, Interferon Type I therapeutic use, Neoplasms therapy
- Abstract
Twenty-two patients with advanced cancer were entered into a phase I study of recombinant human interferon beta (IFN-beta). The maximum tolerated dose was 100 X 10(6) IU administered intravenously on a three times weekly schedule, and persistent fever was the dose-limiting toxicity. The majority of patients tolerated administration of IFN-beta well with negligible hematologic toxicity. Details of the clinical effects of escalating doses of recombinant human IFN-beta, administered three times weekly, are described.
- Published
- 1987
184. Retroperitoneal fibrosis following treatment for Hodgkin's disease.
- Author
-
Chao N, Levine J, and Horning SJ
- Subjects
- Adult, Combined Modality Therapy adverse effects, Humans, Male, Mechlorethamine adverse effects, Prednisone adverse effects, Procarbazine adverse effects, Time Factors, Vincristine adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Hodgkin Disease therapy, Radiotherapy, High-Energy adverse effects, Retroperitoneal Fibrosis etiology, Ureteral Obstruction etiology
- Abstract
With improvement and refinement of therapy, the majority of Hodgkin's disease patients are alive and free of disease at 5 years. As these patients continue to be observed, a variety of late complications have been reported. We describe herein three patients who developed retroperitoneal fibrosis following definitive therapy for Hodgkin's disease. The incidence approaches that seen with methysergide.
- Published
- 1987
- Full Text
- View/download PDF
185. Follicular and diffuse mixed small-cleaved and large-cell lymphoma--a clinicopathologic study.
- Author
-
Hu E, Weiss LM, Hoppe RT, and Horning SJ
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Humans, Lymphatic System radiation effects, Lymphoma mortality, Lymphoma therapy, Lymphoma, Follicular mortality, Lymphoma, Follicular therapy, Prognosis, Lymphoma pathology, Lymphoma, Follicular pathology
- Abstract
The clinical records and initial biopsy materials from 76 patients with mixed small-cleaved and large-cell lymphoma containing both a follicular and diffuse architectural pattern were reviewed. The characteristics of this group, treated at Stanford University Medical Center (SUMC) between 1963 and 1983, are described. The 5-year actuarial survival and freedom from progression are 70% and 27.5%, respectively. Classification according to the degree of follicularity indicated that patients with focally follicular areas (ie, less than 25% of the histologic section) have a significantly worse freedom from progression and overall survival at 5 years compared with those patients with a predominantly follicular architecture (ie, greater than 50% follicular areas). Based on our analysis, we feel that the degree of follicularity is an important prognostic factor and that mixed lymphoma patients with only focally follicular areas behave more like an intermediate-grade lymphoma and should be treated aggressively.
- Published
- 1985
- Full Text
- View/download PDF
186. Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation.
- Author
-
Sullivan KM, Appelbaum FR, Horning SJ, Rosenberg SA, and Thomas ED
- Subjects
- Antibodies, Monoclonal therapeutic use, Combined Modality Therapy, Cyclophosphamide therapeutic use, Hodgkin Disease drug therapy, Hodgkin Disease radiotherapy, Humans, Lymphoma drug therapy, Lymphoma radiotherapy, Risk, Transplantation, Autologous, Transplantation, Homologous, Transplantation, Isogeneic, Whole-Body Irradiation, Bone Marrow Transplantation, Hodgkin Disease therapy, Lymphoma therapy
- Abstract
Despite substantial progress in curative therapy of malignant lymphomas, some patients fail current treatment and die of refractory disease. Although Although high-dose chemotherapy and supralethal total body irradiation followed by bone marrow transplantation may salvage and cure a proportion of these refractory patients, treatment of such end-stage patients with marrow grafting often fails because of resistant disease or transplant-related complications. Using the analogy of transplantation in the early phases of acute and chronic leukemias, results of marrow transplant in Hodgkin's disease and non-Hodgkin's lymphoma might be improved if performed earlier in the course of the malignancy. The following collaborative report by the Seattle and Stanford groups examines current results of conventional lymphoma therapy to define subgroups of patients with "high-risk" lymphoma for whom early marrow transplant might be offered to control otherwise incurable disease.
- Published
- 1986
- Full Text
- View/download PDF
187. Hypercalcemia and vitamin D metabolism in Hodgkin's disease. Is there an underlying immunoregulatory relationship?
- Author
-
Rieke JW, Donaldson SS, and Horning SJ
- Subjects
- Adolescent, Hodgkin Disease complications, Hodgkin Disease immunology, Humans, Hypercalcemia etiology, Hypercalcemia immunology, Male, Paraneoplastic Endocrine Syndromes immunology, Calcitriol physiology, Hodgkin Disease metabolism, Hypercalcemia metabolism, Paraneoplastic Endocrine Syndromes metabolism
- Abstract
Hypercalcemia is not common in Hodgkin's disease, but in reported cases is often unassociated with bone involvement. A case is presented demonstrating a mechanism involving elevated levels of 1,25-dihydroxy vitamin D3 (calcitriol). Similar cases in the literature are reviewed. Data implicating calcitriol as a hematolymphoid regulatory hormone are discussed as they may relate to lymphomas, leukemias, and paraneoplastic lymphocyte and monocyte/macrophage activity.
- Published
- 1989
- Full Text
- View/download PDF
188. Hodgkin's disease in homosexual men with generalized lymphadenopathy.
- Author
-
Schoeppel SL, Hoppe RT, Dorfman RF, Horning SJ, Collier AC, Chew TG, and Weiss LM
- Subjects
- Adult, Biopsy, Bone Marrow pathology, Hodgkin Disease pathology, Humans, Hyperplasia, Lymph Nodes pathology, Lymphatic Diseases pathology, Male, Neoplasm Staging, Skin Neoplasms pathology, Hodgkin Disease complications, Homosexuality, Lymphatic Diseases complications
- Published
- 1985
- Full Text
- View/download PDF
189. How much MOPP?
- Author
-
Horning SJ
- Subjects
- Dose-Response Relationship, Drug, Humans, Mechlorethamine, Prednisone, Procarbazine, Vincristine, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Hodgkin Disease drug therapy
- Published
- 1989
- Full Text
- View/download PDF
190. Comparison of "host cell infiltrates" in patients with follicular lymphoma with and without spontaneous regression.
- Author
-
Strickler JG, Copenhaver CM, Rojas VA, Horning SJ, and Warnke RA
- Subjects
- Antibodies, Monoclonal, B-Lymphocytes pathology, Histocytochemistry, Humans, Immunoenzyme Techniques, Leukocyte Count, Macrophages pathology, T-Lymphocytes pathology, T-Lymphocytes, Helper-Inducer pathology, Lymphoma pathology
- Abstract
The "host cell infiltrates" in five patients with low-grade follicular lymphoma who had spontaneous regression without therapy were studied with the use of immunohistochemical methods applied to frozen sections. These infiltrates were compared with the "host cell infiltrates" in six patients with follicular lymphoma with progressive disease. The group with progressive disease was selected to be similar to the group with spontaneous regression in age, sex, histologic characteristics, and stage of disease. The patients with spontaneous regression had significantly more T-helper cells in the host cell infiltrate than the control patients. There were no statistically significant differences between the two groups in numbers of cytotoxic/suppressor T-cells, macrophages, Tac-positive cells, Leu-7-positive cells, or proliferating cells.
- Published
- 1988
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.